Turnstone Biologics Corp
NASDAQ:TSBX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its Industry Average (6.9), the stock would be worth $-0.73 (305% downside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -3.3 | $0.36 |
0%
|
| Industry Average | 6.9 | $-0.73 |
-305%
|
| Country Average | 1.5 | $-0.16 |
-144%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| US |
T
|
Turnstone Biologics Corp
NASDAQ:TSBX
|
8.2m USD | -3.3 | -0.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -1 260 263.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.6B USD | 4.6 | 89.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.6B USD | 3.8 | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.4B USD | 3.7 | 19.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 966.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.6B USD | 7.4 | 27.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.7B USD | 5.6 | 16.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 14.8 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.8 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD | 1.5 | 29.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.9 |
| Median | 1.5 |
| 70th Percentile | 2.9 |
| Max | 566 432.7 |
Other Multiples
Turnstone Biologics Corp
Glance View
Turnstone Biologics Corp is a US-based company operating in Biotechnology industry. The company is headquartered in La Jolla, California and currently employs 108 full-time employees. The company went IPO on 2023-07-21. Turnstone Biologics Corp. is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The firm is focused on developing tumor infiltrating lymphocytes (TIL) therapies designed to drive clinical benefit and curative outcomes across multiple solid tumors. Its selected TIL approach focuses on selecting and expanding potent tumor-reactive T cells to overcome the limitations of bulk TILs. Its pipeline includes TIDAL-01 and TIDAL-02. Its lead selected TIL product candidate, TIDAL-01, utilizes an unbiased identification and functional screening process to isolate and selectively expand the breadth of tumor-reactive TILs from the patient’s tumor. Its next selected TIL program, TIDAL-02, is being designed to encompass a streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.
